BioCentury

12:53 AM GMT, Jun 8, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Wilex reports final Mesupron data

Wilex AG (Xetra:WL6) said 200 and 400 mg daily oral Mesupron plus weekly IV Gemzar gemcitabine led to overall

Read the full 199 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.